Circulating Tumor DNA in Early Breast Cancer: A Review - PubMed
an hour ago
- #Early Breast Cancer
- #Circulating Tumor DNA
- #Biomarker
- ctDNA can detect minimal residual disease, monitor treatment, and spot recurrence earlier than standard methods.
- Dynamics of ctDNA during neoadjuvant therapy correlate with treatment response and long-term outcomes.
- ctDNA positivity after curative therapy strongly predicts future distant recurrence.
- Emergence of ctDNA during surveillance precedes clinical diagnosis of metastatic disease.
- Evidence for improved outcomes with ctDNA-guided management is still limited.
- Optimal timing and frequency of ctDNA testing remain uncertain.
- Ongoing trials are evaluating if ctDNA-guided treatment can improve patient outcomes.